NF-κB localization in multiple myeloma plasma cells and mesenchymal cells

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 52-60

  Conticello, Concetta ^a   Giuffrida, Raffaella ^a   Adamo, Luana ^a   Anastasi, Gabriele ^a   Martinetti, Daniela ^a   Salomone, Edvige ^b   Colarossi, Cristina ^a   Amato, Gabriella ^a   Gorgone, Ausilia ^c   Romano, Alessandra ^c   Iannolo, Gioacchin ^a   De Maria, Ruggero ^d   Giustolisi, Rosario ^a   Gulisano, Massimo ^a,c   Di Raimondo, Francesco ^c  

^a Mediterranean Institute of Oncology   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Bortezomib; Mesenchymal cells; Multiple myeloma; NF B

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CANCER RESISTANCE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MESENCHYME CELL; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MESODERM; MULTIPLE MYELOMA; NF-KAPPA B; PLASMA CELLS; PYRAZINES;

EID: 78650176111     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.023     Document Type: Article

References (46)

1. Hussein M.A., Juturi J.V., Lieberman I. Multiple myeloma: present and future. Curr Opin Oncol 2002, 14:31-35.
2. Feinman R., Koury J., Thames M., et al. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999, 93:3044-3052.
3. Hoffmann A., Baltimore D. Circuitry of nuclear factor κB signaling. Imm Rev 2006, 210:171-186.
4. Wan F., Lenardo M.J. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res 2010, 20(January (1)):24-33.
5. Panwalkar A., Verstovsek S., Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004, 100:1578-1589.
6. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002, 99:4079-4086.
7. Senftleben U., Cao Y., Xiao G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293(5534):1495-1499.
8. Xiao G., Harhaj E.W., Sun S.C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001, 7(2):401-409.
9. An W.G., Hwang S.G., Trepel J.B., Blagosklonny M.V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14:1276-1283.
10. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000, 18:109-121.
11. Hata H., Xiao H., Petrucci M.T., et al. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993, 81:3357-3364.
12. Chauhan D., Uchiyama H., Akbarali Y., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87:1104-1112.
13. Barlogie B., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma. Blood 2004, 103:20-32.
14. Mitsiades C.S., Mitsiades N.S., Richardson P.G., et al. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007, 101(July (4)):950-968.
15. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
16. Baumann P., Mandl-Weber S., Oduncu F., Schmidmaier R. Alkylating agents induce activation of NFkappaB in multiple myeloma cells. Leuk Res 2008, 32:1144-1147.
17. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
18. Andela V.B., Schwarz E.M., Puzas J.E., et al. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res 2000, 60:6557-6562.
19. Endo T., Nishio M., Enzler T., et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007, 109:703-710.
20. Lam L.T., Davis R.E., Pierce J., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11:28-40.
21. Houldsworth J., Mathew S., Rao P.H., et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996, 87:25-29.
22. Frelin C., Imbert V., Griessinger E., et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005, 105:804-811.
23. Conticello C., Adamo L., Vicari L., et al. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol 2008, 120:19-30.
24. Braun T., Carvalho G., Coquelle A., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
25. Richardson P.G., Anderson K.C. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003, 1:596-600.
26. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
27. Gilmore T.D. Multiple myeloma: lusting for NF-kappaB. Cancer Cell 2007, 12:95-97.
28. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
29. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
30. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9:1136-1144.
31. Fracchiolla N.S., Lombardi L., Salina M., et al. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene 1993, 8:2839-2845.
32. Trecca D., Guerrini L., Fracchiolla N.S., et al. Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities. Oncogene 1997, 14:791-799.
33. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647.
34. Hideshima T., Neri P., Tassone P., et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006, 12:5887-5894.
35. Ni H., Ergin M., Huang Q., et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001, 115:279-286.
36. Bharti A.C., Donato N., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171:3863-3871.
37. Markovina S., Callander N.S., O'Connor S.L., et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008, 6:1356-1364.
38. Hideshima T., Ikeda H., Chauhan D., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
39. Di Raimondo F., Conticello C. Captivating Bortezomib: an active but still mysterious drug. Leuk Res 2010, 34(4):411-412. Epub 2009 Oct 12. PubMed PMID: 19819547.
40. McConkey D.J. Bortezomib paradigm shift in myeloma. Blood 2009, 114:931-932.
41. 2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65(9):3828-3836.
42. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10(11):3839-3852.
43. Kikuchi J, Wada T, Shimizu R, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010 (March). [Epub ahead of print].
44. Qin J.Z., Ziffra J., Stennett L., et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005, 65(14):6282-6293.
45. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61(7):3071-3076.
46. Podar K., Shringarpure R., Tai Y.T., et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004, 64(20):7500-7506.